Profitability
This table compares Sernova and Eliem Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Sernova | N/A | N/A | -283.67% |
Eliem Therapeutics | N/A | -47.03% | -45.97% |
Earnings and Valuation
This table compares Sernova and Eliem Therapeutics”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Sernova | N/A | N/A | -$23.65 million | ($0.05) | -3.11 |
Eliem Therapeutics | N/A | N/A | -$35.12 million | ($0.53) | -2.40 |
Institutional and Insider Ownership
69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Sernova has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500.
About Sernova
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
About Eliem Therapeutics
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.